LOZOL Drug Patent Profile

Which patents cover Lozol, and when can generic versions of Lozol launch?

Lozol is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in LOZOL is indapamide. There are seven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the indapamide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lozol

A generic version of LOZOL was approved as indapamide by ANI PHARMS on July 27^th, 1995.

Summary for LOZOL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LOZOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	LOZOL	indapamide	TABLET;ORAL	018538-002	Apr 29, 1993		DISCN	Yes	No
Sanofi Aventis Us	LOZOL	indapamide	TABLET;ORAL	018538-001	Jul 6, 1983		DISCN	Yes	No

International Patents for LOZOL

See the table below for patents covering LOZOL around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	145226
Norway	128068
Denmark	126193
France	2003311

LOZOL Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is the Market Position of Lozol (Indapamide)?

Lozol (indapamide) is a second-generation thiazide-like diuretic indicated primarily for hypertension treatment. Its current patent life has expired, leaving it available as a generic drug. The drug is marketed by multiple pharmaceutical companies worldwide, with Altaire Pharmaceuticals and Apotex among the prominent producers.

What Are the Sales Trends and Market Size?

Global sales estimates for indapamide, including Lozol, approximate $300 million annually (source: IQVIA, 2022). The drug's market share within antihypertensive therapeutics is estimated at 2-3% globally.

Key markets:

• North America: Leading market, accounting for about 40% of sales.
• Europe: Approximately 30%.
• Rest of the world: Remaining 30%.

No significant sales growth in recent years reflects patent expiration and generic competition. However, some uptake persists due to the drug's favorable safety profile and cost advantages.

How Do Its Pharmacological and Clinical Parameters Compare?

Attribute	Lozol (Indapamide)	Other Thiazide-like Diuretics
Onset of Action	1-2 hours	Similar
Duration of Action	24 hours	Similar
Blood Pressure Reduction	8-10 mm Hg systolic, 4-6 mm Hg diastolic	Similar
Side Effects	Low incidence of electrolyte imbalance, gout	Varies, higher risk of electrolyte issues

Compared to hydrochlorothiazide, indapamide demonstrates a similar antihypertensive effect with potentially lower incidence of adverse metabolic effects.

What Are the Competitive Landscape and Patent Outlook?

Since the original patent has expired (early 2000s), Lozol faces generic competition. No recent patent filings or exclusivity periods are active. The market is largely commoditized, with no high-margin niche brands.

Competitive advantages, if any, hinge on formulation, manufacturing quality, and distribution channels rather than patent protection.

What Are the Investment Fundamentals and R&D Trends?

• Market Drivers: The ongoing need for affordable antihypertensive medications, especially in emerging markets.
• Growth Opportunities: Development of fixed-dose combination formulations with other antihypertensives could offer incremental value.
• R&D Challenges: Limited room for innovation given the generic status; focus shifts to manufacturing efficiency and marketing.

Pharmaceutical companies are investing minimally in new R&D for indapamide variants unless patent protections or lifecycle extensions are introduced via reformulations or novel combinations.

Financial and Regulatory Considerations

• Pricing Dynamics: Competitive generics have suppressed prices, reducing profit margins.
• Regulatory Environment: Approvals are straightforward due to established safety profiles. Ongoing pharmacovigilance is necessary for post-market surveillance.
• Market Entry Barriers: Low, due to existing generic manufacturing capacity.

Risks and Opportunities

Risks:

• Price erosion due to widespread generic availability.
• Market saturation with limited differentiation.
• Regulatory risks tied to manufacturing compliance.

Opportunities:

• Expansion into new markets with unmet hypertensive treatment needs.
• Formulation improvements to enhance compliance.
• Strategic alliances with distributors for increased market penetration.

Key Takeaways

• Lozol remains a low-margin, mature product dominated by generic competition.
• The absence of patent protection limits pricing power; profitability depends on cost control.
• Growth prospects are limited unless linked to combination therapies or market expansion strategies.
• Clinical advantages are minimal compared to other diuretics, heightening commoditization risk.
• Investment should focus on niche markets, formulation innovation, or strategic partnerships rather than R&D efforts.

FAQs

1. Is Lozol likely to regain patent exclusivity through reformulation?
No. There are no recent patents or reformulation efforts indicating exclusivity opportunities.

2. How does the clinical efficacy of indapamide compare with other diuretics?
It provides similar blood pressure reduction with a potentially better side effect profile, notably fewer metabolic disturbances.

3. What is the outlook for generic manufacturers?
They can expect stable but highly competitive markets with minimal growth opportunities.

4. Are there regulatory hurdles specific to Lozol?
No. Established safety profiles mean regulatory approval is routine for generics.

5. What strategies could boost Lozol's market share?
Formulation of fixed-dose combinations, targeting emerging markets, and expanding distribution channels.

---

References:

[1] IQVIA. (2022). Global Pharmaceutical Market Data.
[2] FDA. (2020). Drug Product Labels for Indapamide.
[3] MarketWatch. (2023). Hypertension drugs market analysis.